Company Profile
Structure Therapeutics Stock Price, News & Analysis
- Ticker:
- GPCR
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
48.69 USD (-0.88%)
Close
Last updated: July 27, 2026
2.64B USD
Market cap
Why the stock is moving
As of Jul 27, 2026, GPCR closed down 0.88% at $48.69. No new same-company headline was identified in the current news window.
Company overview
Business overview
Structure Therapeutics is a GPCR-focused company developing oral small-molecule therapies for metabolic and inflammatory diseases. Its platform aims to combine validated biology with convenient dosing.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Structure Therapeutics sits in advanced biotechnology.
Business Model Characteristics
The business depends on clinical data, receptor biology, and the possibility of building a differentiated oral therapeutics franchise.
Position Within the Biotechnology Landscape
Structure Therapeutics is a platform small-molecule name with meaningful upside if the science translates clinically.
Future catalysts
Structure Therapeutics's catalyst is GSBR-1290 in obesity, where dose, tolerability, and efficacy updates decide whether the oral GLP-1 story stays competitive. The next data point matters because the obesity field is still sorting out the winners.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
KYMR · Source: Kymera
- 02
- 03
- 04
- 05
Avalo Therapeutics to Participate in the BTIG Biotechnology Conference
AVTX · Source: Avalo Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Structure Therapeutics (GPCR)?
Structure Therapeutics (GPCR) most recently closed at 48.69 USD, a -0.88% move versus the previous session.
What is the market cap of Structure Therapeutics (GPCR)?
Structure Therapeutics currently has a market capitalization of 2.64B USD on BioPharmSignal.
What does Structure Therapeutics do?
Structure Therapeutics is a GPCR-focused company developing oral small-molecule therapies for metabolic and inflammatory diseases. Its platform aims to combine validated biology with convenient dosing.
On which exchange is GPCR stock listed?
Structure Therapeutics (GPCR) is associated with NASDAQ, United States, Biopharma.
What is GSBR-1290?
Structure Therapeutics's catalyst is GSBR-1290 in obesity, where dose, tolerability, and efficacy updates decide whether the oral GLP-1 story stays competitive.
Which conditions is Structure Therapeutics targeting with GSBR-1290?
Structure Therapeutics is associated with metabolic disease, obesity based on its company overview and current catalyst commentary.
How does Structure Therapeutics describe recent progress with GSBR-1290?
Structure Therapeutics's catalyst is GSBR-1290 in obesity, where dose, tolerability, and efficacy updates decide whether the oral GLP-1 story stays competitive.
What is GLP-1?
Structure Therapeutics's catalyst is GSBR-1290 in obesity, where dose, tolerability, and efficacy updates decide whether the oral GLP-1 story stays competitive.